Sprott Inc. Gain Therapeutics, Inc. Transaction History
Sprott Inc.
- $1.41 Billion
- Q4 2024
A detailed history of Sprott Inc. transactions in Gain Therapeutics, Inc. stock. As of the latest transaction made, Sprott Inc. holds 14,000 shares of GANX stock, worth $37,380. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,000Holding current value
$37,380% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding GANX
# of Institutions
30Shares Held
2.69MCall Options Held
5.7KPut Options Held
10.6K-
David Einhorn Greenlight Capital Inc | New York, Ny588KShares$1.57 Million0.1% of portfolio
-
Dme Capital Management, LP New York, NY566KShares$1.51 Million0.06% of portfolio
-
Geode Capital Management, LLC Boston, MA267KShares$714,0140.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA177KShares$472,7900.0% of portfolio
-
Joel Greenblatt Gotham Asset Management, LLC | New York, Ny158KShares$422,2730.0% of portfolio
About Gain Therapeutics, Inc.
- Ticker GANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,883,400
- Market Cap $31.7M
- Description
- Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietar...